Anavex Life Sciences Corporation
AVXL
Market Cap$828.02M
Close$
$1.58
83.2% downside
Current Fair Value
83.2% downsideOvervalued by 83.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $828.02 Million |
|---|---|
| Enterprise Value | $727.66 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.52 |
| Beta | 0.8 |
| Outstanding Shares | 85,380,587 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -23.57 |
|---|---|
| PEG | 23.57 |
| Price to Sales | - |
| Price to Book Ratio | 9.4 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -17.62 |
| Enterprise Value to Net Income | -31 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Anavex Life Sciences Corporation
CEO: Christopher Missling Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, ...